The enhanced anti-tumor immunity in immunogenic tumors may be ascribed for the inhibition of PTP1B/PTPN2 in T cells, whereas in chilly tumors, Compound-182 elicited direct consequences on both tumor cells and T cells. Importantly, therapy with Compound-182 rendered in any other case resistant tumors